Vaccine
AssigneeGlaxosmithkline Biologicals SA
InventorsCarine Capiau, Pierre Michel Desmons, Craig Antony Joseph Laferriere, Jan Poolman, Jean-Paul Prieels
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.
Claims4
A method of producing a multivalent immunogenic composition comprising isolated capsular polysaccharides of at least four serotypes of Streptococcus pneumoniae, each of said isolated capsular polysaccharides conjugated to isolated protein D from Haemophilus influenzae that lacks a leader peptide and the N-terminal cysteine and contains a T-helper epitope, wherein the protein D is not lipidated, comprising the steps of:
- isolating capsular polysaccharides from at least four serotypes of Streptococcus pneumoniae;
- activating each of the isolated capsular polysaccharides;
- conjugating each of the isolated activated capsular polysaccharides to isolated protein D from Haemophilus influenzae that lacks a leader peptide and the N-terminal cysteine and contains a T-helper epitope, wherein the protein D is not lipidated and
- mixing together the conjugated capsular polysaccharide of each of the at least four serotypes of the Streptococcus pneumoniae to produce the multivalent immunogenic composition.
Dependencies are inferred from the claim text.